Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pending Calif. Consumer Products Reg Inconsistent, Unfair – Trade Groups

This article was originally published in The Tan Sheet

Executive Summary

The Personal Care Products Council and the Consumer Healthcare Products Association fault the latest and likely last draft of California’s Safer Consumer Products regs for its lack of a weight-of-evidence approach to decision making and inadequate trade-secret protections, among other shortcomings.

You may also be interested in...



California DTSC’s Draft Work Plan Includes Personal Care, But Few Surprises

“Beauty, personal care and hygiene” as one of seven product categories could be priorities in the next round of product selections in California’s Safer Consumer Products program. PCPC welcomes the direction DTSC appears to be taking toward more active industry engagement over the next three years.

California DTSC’s Draft Work Plan Includes Personal Care, But Few Surprises

“Beauty, personal care and hygiene” as one of seven product categories could be priorities in the next round of product selections in California’s Safer Consumer Products program. PCPC welcomes the direction DTSC appears to be taking toward more active industry engagement over the next three years.

California Safer Consumer Products Compliance Costs Will Vary Widely

The state toxic substances authority says “a simple single-chemical alternatives analysis” could cost $2,000 to $3,000, a moderately complex analysis with existing data “would be in the tens of thousands of dollars” and one “of greater complexity requiring extensive testing” could run in the hundreds of thousands.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106422

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel